Jelena Jović

Position:Senior researcher

Jelena Jović is a Senior Researcher at the Center for Biosystems within the BioSense Institute. During her PhD research on the characterisation of novel pharmaceutical formulations of traditional antidiabetic agents at the Medical faculty, University of Novi Sad, she gained experience in performing pharmacokinetic and pharmacodynamic studies. Currently, her second PhD thesis, conducted at the Technical University of Munich, is pending submission. There, her research was focused on investigating the role of intestinal microbiota in inflamatory bowel disease pathogenesis, using both traditional microbiological techniques and next generation sequencing (NGS) technology. At the BioSense Institute, her research interests are directed towards soil microbiome and its applications in sustainable agriculture.

Center:

CBS

Projects:

1. Soil Health Guards – Cultivating Soil Connectivity: Empowering Farmers and Youth Community as Citizen Scientists to Monitor Soil Health and Biodiversity

Publications:

1. Schaubeck M, Clavel T, Calasan J, Lagkouvardos I, Haange SB, Jehmlich N, Basic M, Dupont A, Hornef M, Von Bergen M, Bleich A. Dysbiotic gut microbiota causes transmissible Crohn’s disease-like ileitis independent of failure in antimicrobial defence. Gut. 2016 Feb 1;65(2):225-37. doi: 10.1136/gutjnl-2015-309714
2. Walker A, Pfitzner B, Harir M, Schaubeck M, Calasan J, Heinzmann SS, Turaev D, Rattei T, Endesfelder D, Castell WZ, Haller D. Sulfonolipids as novel metabolite markers of Alistipes and Odoribacter affected by high-fat diets. Sci Rep. 2017 Sep 8;7(1):11047. doi: 10.1038/s41598-017-10369-z.
3. Andrejić BM, Mijatović VM, Samojlik IN, Horvat OJ, Ćalasan JD, Đolai MA. The influence of chronic intake of saccharin on rat hepatic and pancreatic function and morphology: gender differences. Bosn J Basic Med Sci. 2013 May; 13(2): 94–99. doi: 10.17305/bjbms.2013.2372
4. Golocorbin-Kon S, Calasan J, Milijasevic B, Vukmirovic S, Lalic-Popovic M, Mikov M, Al-Salami H. High-loading dose of microencapsulated gliclazide formulation exerted a hypoglycaemic effect on type 1 diabetic rats and incorporation of a primary deconjugated bile acid, diminished the hypoglycaemic antidiabetic effect. Eur J Drug Metab Pharmacokinet. 2017 Dec;42(6):1005-1011. doi: 10.1007/s13318-017-0415-0.
5. Jović J, Milijašević B, Vukmirović S, Vasović V, Mikov M, Mooranian A, Al-Salami H, Golocorbin-Kon S. Pharmacokinetic and drug absorption profiles of the anti-hyperglycaemic agent gliclazide in oral tissue-targeted microcapsules in rats. Scripta Medica. 2020;51(1):15-20. doi: 10.5937/scriptamed51-25521